Q-Line Biotech Limited (NSE:QLINE)
India · Delayed Price · Currency is INR 611.65
+9.90 (1.65%)
At close: Oct 14, 2026
Q-Line Biotech Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 557.22 | 192.11 | 344.49 | 320.97 | - |
Depreciation & Amortization | 88.58 | 70.34 | 39.06 | 21.16 | - |
Other Amortization | 19.32 | - | 0.21 | 0.21 | - |
Loss (Gain) From Sale of Assets | -0.61 | 0.26 | -3.94 | -0.02 | - |
Loss (Gain) From Sale of Investments | - | 169.7 | - | - | - |
Provision & Write-off of Bad Debts | 4.83 | 33.39 | 8.24 | 4.9 | - |
Other Operating Activities | 101.41 | 339.14 | -86.1 | -124.33 | - |
Change in Accounts Receivable | -437.52 | -591.48 | 57.9 | 89.57 | - |
Change in Inventory | -47.47 | 213.08 | -616.47 | -82.3 | - |
Change in Accounts Payable | -62.8 | -113.43 | 192.78 | 30.1 | - |
Change in Other Net Operating Assets | -59.22 | -141.01 | -177.98 | -10.58 | - |
Operating Cash Flow | 163.76 | 172.1 | -241.79 | 249.69 | - |
Operating Cash Flow Growth | -4.85% | - | - | - | - |
Investing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Capital Expenditures | -359.14 | -701 | -489.01 | -262.67 | - |
Sale of Property, Plant & Equipment | 4.87 | 0.39 | 8.14 | 0.08 | - |
Sale (Purchase) of Real Estate | 12.76 | -106.73 | 0.26 | -33.45 | - |
Investment in Securities | - | -2.82 | -0.05 | - | - |
Other Investing Activities | 47.35 | 35.42 | 22.9 | 19.32 | - |
Investing Cash Flow | -294.16 | -774.74 | -446.88 | -263.14 | - |
Financing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Short-Term Debt Issued | - | - | 24.76 | 243.15 | - |
Long-Term Debt Issued | 605.33 | 680.97 | 207.86 | 58.85 | - |
Total Debt Issued | 605.33 | 680.97 | 232.62 | 301.99 | - |
Net Debt Issued (Repaid) | 605.33 | 680.97 | 232.62 | 301.99 | - |
Issuance of Common Stock | 5.25 | - | - | - | - |
Other Financing Activities | -194.17 | -149.13 | -62.75 | -37.96 | - |
Financing Cash Flow | 416.41 | 531.83 | 169.86 | 264.03 | - |
Net Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Miscellaneous Cash Flow Adjustments | - | - | 0 | - | - |
Net Cash Flow | 286.01 | -70.81 | -518.81 | 250.58 | - |
Free Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -195.38 | -528.9 | -730.8 | -12.98 | - |
Free Cash Flow Growth | - | - | - | - | - |
Free Cash Flow Margin | -5.72% | -16.89% | -35.89% | -0.71% | - |
Free Cash Flow Per Share | -12.20 | -33.58 | -46.40 | -0.82 | - |
Levered Free Cash Flow | -419.59 | -596.5 | -797.87 | 326.29 | - |
Unlevered Free Cash Flow | -301.37 | -511.99 | -761 | 345.51 | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash Interest Paid | 188.64 | 134.59 | 58.98 | 30.75 | - |
Cash Income Tax Paid | 260.27 | 83.98 | 92.61 | 124.27 | - |
Change in Working Capital | -607 | -632.84 | -543.77 | 26.79 | - |